<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03275636</url>
  </required_header>
  <id_info>
    <org_study_id>DKMS-16-01</org_study_id>
    <secondary_id>2015-005399-12</secondary_id>
    <nct_id>NCT03275636</nct_id>
  </id_info>
  <brief_title>Haploidentical Donor vs mMUD in Hematological Malignancies</brief_title>
  <acronym>HAMLET</acronym>
  <official_title>A Randomized Controlled Trial Comparing Outcome After Hematopoietic Cell Transplantation From a Partially Matched Unrelated Versus Haploidentical Donor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DKMS gemeinnützige GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DKMS gemeinnützige GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this trial is to compare the outcome after partially matched (single mismatch)&#xD;
      unrelated donor transplantation with haploidentical transplantation in a randomized&#xD;
      controlled setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For patients with an indication for allogeneic HCT, the search for a stem cell donor is a&#xD;
      challenge. 20% of patients who need an allograft have an HLA-identical sibling available, and&#xD;
      for approximately 70% of the remaining patients, a suitable, HLA-well-matched (10/10),&#xD;
      unrelated volunteer can be found. For the remaining patients, partially matched (single&#xD;
      mismatch) unrelated donors or haploidentical donors are alternative options.&#xD;
&#xD;
      Recently published retrospective single center and registry studies suggest comparable&#xD;
      outcomes for HCT from unrelated donors matched at HLA -A, -B, -C, and -DRB1 and&#xD;
      haploidentical donors. The number of haploidentical HCT evaluated in these studies was still&#xD;
      relatively small and a selection bias for the retrospective comparisons cannot be excluded.&#xD;
&#xD;
      The goal of this trial is to evaluate overall survival of patients with high-risk AML, ALL or&#xD;
      MDS after partially matched unrelated or haploidentical donor transplantation..&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival calculated from the time of randomization will be the primary endpoint of this trial. Death from any reason will be considered as event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Engraftment rate</measure>
    <time_frame>day 56</time_frame>
    <description>Engraftment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune-reconstitution rate</measure>
    <time_frame>day56</time_frame>
    <description>Immune-reconstitution rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections</measure>
    <time_frame>2 months after HCT</time_frame>
    <description>Severe infections rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival</measure>
    <time_frame>1 year</time_frame>
    <description>Event Free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft vs Host Disease</measure>
    <time_frame>1 year</time_frame>
    <description>Graft vs Host Disease rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft vs Host Disease-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Graft vs Host Disease-free survival rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">266</enrollment>
  <condition>AML</condition>
  <condition>ALL</condition>
  <condition>MDS</condition>
  <arm_group>
    <arm_group_label>Haploidentical donor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peripheral blood stem cells from Haploidentical donor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>partially matched unrelated donor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peripheral blood stem cells from unrelated donor with a single allele or antigen mismatch at HLA-A, -B, -C, or -DRB1 and no concurrent DQB1 mismatch (9/10) shown by confirmatory typing</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peripheral blood stem cells</intervention_name>
    <description>Hematopoietic stem cell transplantation with PBSC</description>
    <arm_group_label>Haploidentical donor</arm_group_label>
    <arm_group_label>partially matched unrelated donor</arm_group_label>
    <other_name>PBSC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Eligible diagnoses are listed below:&#xD;
&#xD;
             AML with adverse risk genetic abnormalities (according to the ELN guidelines)1. AML&#xD;
             with intermediate genetic abnormalities (according to ELN guidelines) either in first&#xD;
             complete remission, after relapse, or by chemotherapy-refractory disease.&#xD;
&#xD;
             AML with favourable genetic abnormalities (according to ELN guidelines) after relapse&#xD;
             or by chemotherapy-refractory disease, except APL.&#xD;
&#xD;
             AML with undefined genetic risk classification after relapse or with&#xD;
             chemotherapy-refractory disease.&#xD;
&#xD;
             AML arising from myelodysplastic syndrome (MDS) or a myeloproliferative neoplasia,&#xD;
             except if favourable genetic abnormalities (according to ELN guidelines) are present.&#xD;
&#xD;
             Therapy-related myeloid neoplasia except if favorable genetic abnormalities (according&#xD;
             to ELN guidelines) are present.&#xD;
&#xD;
             MDS with high risk or very high risk disease (according to the IPSS-R score)2.&#xD;
&#xD;
             First CR of high-risk ALL, defined by one or more of these:&#xD;
&#xD;
               -  Early or mature T-ALL (CD1a negative).&#xD;
&#xD;
               -  Pro B-ALL with t(4v;11); KMT2A-rearrangements.&#xD;
&#xD;
               -  Presence of BCR-ABL and/or t(9;22).&#xD;
&#xD;
               -  Persistence of minimal residual disease after the second induction course. ALL&#xD;
                  with or without complete remission after salvage therapy following poor response&#xD;
                  to induction therapy.&#xD;
&#xD;
             ALL after haematological or molecular relapse.&#xD;
&#xD;
          2. Fit for transplant according to physician judgement.&#xD;
&#xD;
          3. No history of cardiac disease and absence of active symptoms, otherwise, documented&#xD;
             left ventricular ejection fraction ≥40%.&#xD;
&#xD;
          4. No history of chronic pulmonary disease and absence of dyspnea. Otherwise, documented&#xD;
             diffusion lung capacity for carbon monoxide (DLCO) ≥40% or FEV1/FVC ≥ 50% despite&#xD;
             appropriate treatment&#xD;
&#xD;
          5. Availability of ≥1 unrelated donor with a single allele or antigen mismatch at HLA-A,&#xD;
             -B, -C, or -DRB1 and no concurrent DQB1 mismatch (9/10) shown by confirmatory typing.&#xD;
&#xD;
          6. Availability of at least one haploidentical donor meeting the following criteria:&#xD;
&#xD;
        Donor is a biologic parent / child of the patient, or haploidentity has been confirmed for&#xD;
        patient's relatives by HLA-Typing.&#xD;
&#xD;
        The donor has expressed his/her will to donate and has no contraindications against a stem&#xD;
        cell donation by medical history.&#xD;
&#xD;
        Donor age is ≥18 years and ≤75 years.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Relapse or graft failure after a first allogeneic transplantation.&#xD;
&#xD;
          2. Thymic ALL in first complete remission.&#xD;
&#xD;
          3. Severe organ dysfunction defined by either of the following three criteria:&#xD;
&#xD;
             Patients who receive supplementary continuous oxygen. Serum bilirubin &gt;1.5 x ULN (if&#xD;
             not considered Gilbert-Syndrome) or ASAT/ALAT &gt;5 x ULN.&#xD;
&#xD;
             Estimated Glomerular Filtration Rate (GFR) &lt; 40 mL/min&#xD;
&#xD;
          4. Uncontrolled infection at the time of enrollment.&#xD;
&#xD;
          5. Pregnant or breast-feeding women.&#xD;
&#xD;
          6. An HLA-identical sibling donor or 8/8 (HLA-A, -B, -C, or -DRB1) matched unrelated&#xD;
             donor is available and suitable to donate prior to randomization.&#xD;
&#xD;
          7. Men unable or unwilling to use adequate contraception methods from enrollment to&#xD;
             minimum of six months after the last dose of chemotherapy.&#xD;
&#xD;
          8. Women of childbearing potential except those who fulfill the following criteria:&#xD;
             Post-menopausal or post-operative or continuous and correct application of a&#xD;
             contraception method with a Pearl Index &lt;1% or sexual abstinence or vasectomy of the&#xD;
             sexual partner.&#xD;
&#xD;
          9. Simultaneous participation in another clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Schetelig, Prof Dr med</last_name>
    <role>Study Chair</role>
    <affiliation>Universtitätsklinikum Dresden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Trost, MSc</last_name>
    <phone>0049 351210798</phone>
    <phone_ext>28</phone_ext>
    <email>strost@dkms.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tobias Holderried, Dr med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Schetelig, Prof Dr med</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60595</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gesine Bug, Dr med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale)</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lutz Peter Müller, PD Dr med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stefan Klein, PD Dr med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matthias Stelljes, PD Dr med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg Nord</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kerstin Schäfer-Eckhard, Dr med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin Kaufmann, Dr med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wolfgang Bethge, Prof Dr med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 4, 2017</study_first_submitted>
  <study_first_submitted_qc>September 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2017</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haploidentical</keyword>
  <keyword>mismatched unrelated donor</keyword>
  <keyword>hematopoietic stem cell transplantation</keyword>
  <keyword>donor comparison</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

